Phio Pharmaceuticals Reports Widened Q1 Loss Amid Increased R&D for PH-762, Maintains 12-Month Cash Runway

summarizeSummary

Phio Pharmaceuticals reported a significantly wider net loss and increased operating expenses in Q1 2026 due to higher R&D for its PH-762 program, while maintaining a 12-month cash runway and an existing ATM offering for future funding.

check_boxKey Events

• Net Loss More Than Doubled

  The company reported a net loss of $4.0 million for Q1 2026, a significant increase from $1.8 million in Q1 2025.

• Operating Expenses Surge Due to R&D

  Total operating expenses rose 123% to $4.2 million, primarily driven by a 215% increase in research and development expenses to $2.8 million, focused on advancing the PH-762 program.

• Increased Cash Burn

  Cash and cash equivalents decreased by $4.0 million during the quarter, with net cash used in operating activities increasing to $4.0 million from $1.3 million in the prior year period.

• Liquidity and Cash Runway

  Phio Pharmaceuticals holds $17.0 million in cash and cash equivalents as of March 31, 2026, and projects sufficient funds to meet obligations for at least 12 months.

auto_awesomeAnalysis

Phio Pharmaceuticals reported a significant widening of its net loss and increased cash burn in Q1 2026, primarily driven by substantial investments in its PH-762 clinical program. While the increased R&D spend is crucial for advancing its lead product candidate, it has led to a more than doubling of the net loss and operating expenses compared to the prior year. The company's cash and cash equivalents decreased by $4.0 million during the quarter. Despite this, management projects a cash runway of at least 12 months, supported by existing capital and an At-The-Market (ATM) offering program established in April 2026. The ATM program, which allows for the sale of up to $6.36 million in common stock, provides potential future liquidity but also represents significant potential dilution for existing shareholders, especially considering the 13.4 million warrants already outstanding.